Professor Tsila Zuckerman - Details

Dr. Tsila Zuckerman is Director of the Department of Hematology and Bone Marrow Transplantation at Rambam Health Care Campus and Clinical Associate Professor at the Ruth & Bruce Rappaport Faculty of Medicine of the Technion-Israel Institute of Technology. Her teaching activities include coordination of the Preclinical-Clinical Integrated Systems course (Hemato-Oncology) for medical students, instruction of the Capsule course and consultation of clinical-year students. Dr. Zuckerman also heads the Leukemia Research Laboratory at the Clinical Research Institute at Rambam (CRIR) and mentors PhD and MSc students.

Dr. Zuckerman received her MD (with distinction) from the Faculty of Medicine at the Technion in Haifa, Israel and performed her residency in internal medicine at the Carmel Medical Center in Haifa. She went on to complete a three-year clinical and research fellowship in hemato-oncology and bone marrow transplantation (BMT) at the University of Southern California (Los Angeles, CA, USA). Upon her return to Israel, Dr. Zuckerman joined the Department of Hematology at Rambam Health Care Campus. Since 2006, she has been heading the Rambam Bone Marrow Transplantation Unit, where over 2,500 transplants have been performed to date, and the most advanced treatment approaches are being used for the benefit of both patients and BMT donors.

She is the Scientific Secretary of the Israel Association for Bone Marrow Transplantation, a member of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), and a member of the Steering Committee of the Israel Society of Hematology and Transfusion Medicine. She also serves as coordinator of the Integrative Course in Hemato-Oncology at the Faculty of Medicine of the Technion. She is co-author of about 20 scientific articles, published in the leading international journals in the field of hematology, and is a presenter at major national and international meetings.

The major clinical research interest of Dr. Zuckerman focuses on stem cell transplantation in acute leukemia, particularly complications associated with this procedure. Currently, her team is developing an infrastructure for up-to-date cellular therapies, including CAR T-cell therapy. Dr. Zuckerman's other scientific interests include the investigation of intra-patient genetic heterogeneity in acute myeloid leukemia using single cell analysis and contribution of the microenvironment to leukemia initiation and propagation.

Selected Publications

  1. Zuckerman T, Zuckerman E, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM. Bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Brit J Haematol 2001;1112:364-9.

  2. Zuckerman T, Zuckerman E, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM. The effect of anti-viral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001;97:1555-9.

  3. Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, Saleh N, Robert ES, Rowe JM, Kra-Or Z. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003; 101:463-5.

  4. Shlush LI, Chapal-Ilani N, Adar R, Pery N, Maruvka Y, Spiro A, Shouval R, Rowe JM, Tzukerman M, Bercovich D, Izraeli S, Marcucci G, Bloomfield CD, Zuckerman T, Skorecki K, Shapiro E. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and miscrosatellite instability. Blood 2012;120(3):603-12.

  5. Shouval R, Shlush LI, Yehudai-Resheff,S Ali S, Pery N, Shapiro E, Tzukerman M, Rowe JM, Zuckerman T. Single cell analysis exposes intra-tumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis Exp Hematol. 2014;42(6):457-63.

  6. Yehudai-Resheff S., Attias-Turgeman S., Sabbah R., Gabay T., Musallam R., Friedman-Dror A., Zuckerman T. Abnormal Morphological and Functional Nature of Bone Marrow Stromal Cells Provides Preferential Support for Survival of Acute Myeloid Leukemia Cells. Int J Cancer. 2019;144(9):2279-89.